StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)

Close on Nov 18, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Inhibikase Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$65.44M. For fiscal 2025 it was -$51.97M. The highest annual figure on record is -$2.82M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$51.97M–
FY2024Dec 31, 2024-$28.59M–
FY2023Dec 31, 2023-$20.09M–
FY2022Dec 31, 2022-$18.13M–
FY2021Dec 31, 2021-$14.77M–
FY2020Dec 31, 2020-$2.82M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$21.05M–
Q1 FY2026Mar 31, 2026-$17.84M–
Q4 FY2025Dec 31, 2025-$13.78M–
Q3 FY2025Sep 30, 2025-$12.77M–
Q2 FY2025Jun 30, 2025-$10.83M–
Q1 FY2025Mar 31, 2025-$14.60M–
Q4 FY2024Dec 31, 2024-$12.93M–
Q3 FY2024Sep 30, 2024-$5.83M–
Q2 FY2024Jun 30, 2024-$5.05M–
Q1 FY2024Mar 31, 2024-$4.78M–
Q4 FY2023Dec 31, 2023-$4.40M–
Q3 FY2023Sep 30, 2023-$4.77M–
Q2 FY2023Jun 30, 2023-$6.20M–
Q1 FY2023Mar 31, 2023-$4.71M–
Q4 FY2022Dec 31, 2022-$4.33M–
Q3 FY2022Sep 30, 2022-$4.51M–
Q2 FY2022Jun 30, 2022-$4.64M–
Q1 FY2022Mar 31, 2022-$4.64M–
Q2 FY2021Jun 30, 2021-$2.63M–
Q1 FY2021Mar 31, 2021-$2.63M–
Q4 FY2020Dec 31, 2020-$1.20M–
Q3 FY2020Sep 30, 2020-$663.71K–
Q2 FY2020Jun 30, 2020-$413.92K–
Q1 FY2020Mar 31, 2020-$540.02K–

More Inhibikase Therapeutics figures

See a number that looks wrong?